In the Claims:

Please cancel claims 9, 12, 13, and 15-20 without prejudice, and amend claim 11 as follows:

11. (Amended) A composition suitable for administering to a subject comprising a compound in a therapeutically effective amount isolated from cranberry and selected from the group consisting of a phenolic acid, flavanoid, fiber, omega-3-fatty acid, tocochromanol, triterpenoid, ellagic acid, and combinations thereof.

REMARKS

Claims 9 and 11-23 are pending in the application. Claims 9, 12, 13, and 15-20 have been canceled without prejudice as being drawn to a non-elected invention. Claims 11, 14, and 21-23 have been examined.

Claim 11 has been amended herein to specify that the recited composition suitable for administering to a subject comprises a therapeutically effective amount of a compound isolated from cranberry. Support for this amendment can be found in the specification, for example, at page 7, lines 20-25 and at page 10, line 21, to page 11, line 7. No new matter has been added to the application by way of this amendment.

The foregoing claim amendments and cancellations have been made solely for the purpose of expediting prosecution of the present application and should in no way be construed as an acquiescence to any of the Examiner's rejections in this or in any former Office Action issued in the present application. Applicants reserve the right to pursue the subject matter of the present claims prior to being amended herein in this application or in another related application.

In view of the foregoing claim amendments and the arguments set forth below, Applicants respectfully submit that the claims are now in condition for allowance.

Attached hereto is a marked-up version of the changes made to the claims by the amendments requested herein entitled "VERSION WITH MARKINGS TO SHOW CHANGES MADE". For the Examiner's convenience, the claims that will be pending upon entry of this amendment are also attached as Appendix B.

Rejection of Claim 11 Under 35 U.S.C. §102(b)

The Examiner rejects claim 11 under 35 U.S.C. §102(b) as being anticipated by Marwan et al. (J. of Food Science, 47:774-778 (1982); hereafter "Marwan"). The Examiner characterizes